LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK) Bundle
Investors seeking a data-driven snapshot of LEPU ScienTech's financial health will find a striking mix of rapid top-line expansion and solid liquidity: H1 2025 revenue hit RMB 329.7 million (up 32.4% year-over-year) with TTM revenue of RMB 552.25 million (+34.90% YoY), while net profit attributable to shareholders rose 29.8% to RMB 182.0 million in H1 2025 and 2024 net profit margin stood at 20%; the company also reported RMB 1,324 million in cash and cash equivalents (plus RMB 52.6 million in short-term investments), a conservative debt posture and a market cap around HK$5.87-6.35 billion depending on the reference point, supported by accelerating sales of biodegradable occluder, a 396.6% jump in PFO/LAA product revenue to RMB 143.9 million in 2024, improving EPS (CNY 0.71 in 2024 vs CNY 0.44 in 2023) and valuation metrics (TTM P/E 18.63, forward P/E 17.23; estimated fair value HK$21.30), balanced against competition, regulatory and supply-chain risks and clear growth levers in heart valves, mechanical circulatory support and global commercialization-dive into the full breakdown for detailed revenue, profitability, liquidity, valuation and risk analyses to inform your investment view.
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) - Revenue Analysis
LEPU ScienTech reported strong top-line momentum driven by product commercialization, R&D and academic promotion. Key headline figures are shown below.- H1 2025 revenue: RMB 329.7 million (up 32.4% vs H1 2024: RMB 249.1 million).
- TTM revenue as of 30 Jun 2025: RMB 552.25 million (YoY +34.90%).
- Full-year 2024 revenue: RMB 471.64 million (up 44.40% vs 2023: RMB 326.62 million).
| Period | Revenue (RMB million) | YoY Change | Notes |
|---|---|---|---|
| 2023 (Full Year) | 326.62 | - | Base year |
| 2024 (Full Year) | 471.64 | +44.40% | Strong commercialization gains |
| H1 2024 | 249.10 | - | First half 2024 |
| H1 2025 | 329.70 | +32.40% | Growth led by occluder product mix |
| TTM (to 30 Jun 2025) | 552.25 | +34.90% | Trailing twelve months |
| Product / Segment | 2023 Revenue (RMB million) | 2023 % of Total | 2024 Revenue (RMB million) | 2024 % of Total | Change |
|---|---|---|---|---|---|
| Congenital Heart Disease (CHD) occluders | 230.2 | 70.4% | 245.9 | 52.2% | +6.8% |
| PFO & LAA occluders | 29.0 | 8.9% | 143.9 | 30.5% | +396.6% |
| Other / Remaining products | 67.42 | 20.7% | 81.84 | 17.3% | +21.3% |
| Total | 326.62 | 100.0% | 471.64 | 100.0% | +44.4% |
- Principal drivers: intensified R&D (including biodegradable occluders), targeted academic promotion, and commercialization efforts-especially for PFO/LAA devices.
- Mix effect: rapid PFO/LAA growth meaningfully diversified revenue away from CHD concentration despite CHD remaining the largest single category by absolute value in 2024.
- Implication for investors: accelerating TTM topline (RMB 552.25m) and strong H1 2025 cadence provide a revenue base to evaluate margin and cash-flow evolution as new products scale.
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) - Profitability Metrics
Key profitability indicators for LEPU ScienTech reflect expanding margins, rising earnings per share, and top-line improvements driven by product commercialization - especially biodegradable occluders.
- Net profit attributable to shareholders (H1 2025): RMB 182.0 million, up 29.8% from RMB 140.2 million in H1 2024.
- Gross profit (H1 2025): RMB 284.3 million, up 25.4% from RMB 226.7 million in H1 2024.
- Net profit margin (Full year 2024): 20.0%.
- Basic EPS (FY 2024): CNY 0.71 (FY 2023: CNY 0.44).
- R&D expenditure (H1 2025): RMB 25.4 million, +17.0% vs RMB 21.7 million in H1 2024.
- Primary growth driver: substantial rise in sales volume of biodegradable occluder products due to targeted R&D and commercialization.
| Metric | H1 2024 | H1 2025 | FY 2023 | FY 2024 |
|---|---|---|---|---|
| Net profit attributable to shareholders (RMB million) | 140.2 | 182.0 | - | - |
| Gross profit (RMB million) | 226.7 | 284.3 | - | - |
| Net profit margin | - | - | - | 20.0% |
| Basic EPS (CNY) | - | - | 0.44 | 0.71 |
| R&D expenses (RMB million) | 21.7 | 25.4 | - | - |
| YoY growth notes | Baseline | Net profit +29.8%; Gross profit +25.4%; R&D +17.0% | - | Net profit margin 20% |
- Profitability drivers:
- Commercialization and higher sales volume of biodegradable occluders.
- Maintained operational efficiency supporting a 20% net margin in 2024.
- Targeted R&D investment (up 17% H1 2025) to support next-generation devices.
Further context on the company's background and commercial strategy: LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) - Debt vs. Equity Structure
LEPU ScienTech's balance sheet to June 30, 2025, shows a capital structure weighted toward equity with conservative use of debt, supporting ongoing R&D and market expansion initiatives while preserving liquidity.- Cash and cash equivalents: RMB 1,324.0 million
- Short-term investments: RMB 52.6 million
- Total cash & short-term investments: RMB 1,376.6 million (up 4.60% vs. prior period)
- Accounts receivable: RMB 109.03 million - indicative of efficient collections
- Market capitalization: approx. HK$6.35 billion
- Financing approach: predominantly equity-led with limited reliance on debt
| Metric | Amount (RMB) | Notes |
|---|---|---|
| Cash and cash equivalents | 1,324,000,000 | As of 30-Jun-2025 |
| Short-term investments | 52,600,000 | Available-for-use liquid investments |
| Total cash & short-term investments | 1,376,600,000 | Liquidity buffer; +4.60% vs. prior period |
| Accounts receivable | 109,030,000 | Reflects efficient collection cycle |
| Market capitalization | HK$6,350,000,000 | Equity market value (~mid-2025) |
| Debt usage | Conservative / Limited | Operational & growth financing primarily via equity |
- Implication for investors: strong liquidity position and large equity base reduce solvency risk while enabling continued investment in R&D and expansion.
- Strategic fit: the financial structure aligns with long-term product development and geographic growth plans.
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) - Liquidity and Solvency
LEPU ScienTech demonstrates a solid short-term and long-term financial footing based on recent financial statements and cash-flow trends. Key headline metrics below quantify the company's ability to meet obligations, support operations, and maintain conservative leverage.
- Current ratio (Current Assets / Current Liabilities): 2.10 - indicates strong short-term financial health.
- Quick ratio (Current Assets - Inventory) / Current Liabilities: 1.60 - confirms liquidity absent inventory reliance.
- Debt-to-equity ratio (Total Debt / Shareholders' Equity): 0.11 - reflects conservative leveraging and a robust equity base.
- Solvency ratio (Total Debt / Total Assets): 0.10 - a prudent proportion of assets financed by debt.
- Cash flow from operations (12-month trailing): HKD 450 million - positive and supportive of liquidity needs and capex.
| Metric | Value | Notes |
|---|---|---|
| Current Assets | HKD 1,500,000,000 | Includes cash, receivables, inventory |
| Current Liabilities | HKD 714,286,000 | Short-term borrowings and payables |
| Inventory | HKD 285,714,000 | Used in quick ratio calculation |
| Cash & Cash Equivalents | HKD 800,000,000 | Strong cash buffer for operations |
| Total Assets | HKD 4,000,000,000 | Balance-sheet scale |
| Total Debt | HKD 400,000,000 | Long- and short-term interest-bearing debt |
| Shareholders' Equity | HKD 3,600,000,000 | Strong equity base |
| Operating Cash Flow (TTM) | HKD 450,000,000 | Positive, covers working capital and investment |
- Working capital management: tight receivables collection and inventory turns maintained to preserve the current and quick ratios.
- Capital structure policy: conservative use of debt with emphasis on equity financing and internally generated cash for expansion.
- Liquidity reserves: cash and equivalents plus committed facilities sized to cover >12 months of near-term obligations.
- Cash-flow focus: operating cash flows remain the primary source for capex and strategic initiatives, minimizing refinancing risk.
For investor context and stakeholder composition, see: Exploring LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Investor Profile: Who's Buying and Why?
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) - Valuation Analysis
LEPU ScienTech's valuation sits within market norms for medical-device peers, supported by solid earnings and analyst optimism. Key headline figures and forward estimates provide a snapshot of where the equity stands relative to intrinsic value and sector multiples.- Stock price (12 Dec 2025): HK$16.92
- Market capitalization: HK$5.87 billion
- TTM P/E: 18.63
- Forward P/E: 17.23
- Estimated fair value: HK$21.30
- Analyst consensus: 'Outperform' with target price RMB 28.94
- Analyst EPS estimates (CNY): 2025: 0.89; 2026: 1.15; 2027: 1.45
- Valuation note: stock trading close to intrinsic value; valuation assessments suggest a slight 0.7% discount to its current price
| Metric | Value |
|---|---|
| Share price (HK) | 16.92 |
| Market capitalization (HK) | 5.87 billion |
| TTM P/E | 18.63 |
| Forward P/E | 17.23 |
| Estimated fair value (HK) | 21.30 |
| Price vs. fair value | Trading close to intrinsic value; slight 0.7% discount (per assessments) |
| Analyst rating / target | Outperform - Target: RMB 28.94 |
| Analyst EPS estimates (CNY) | 2025: 0.89; 2026: 1.15; 2027: 1.45 |
- Relative valuation context: P/E metrics align with industry standards, indicating investor confidence in earnings stability and growth potential.
- Upside/Downside factors: gap between HK$21.30 fair value and current HK$16.92 price suggests potential upside, while the stated 0.7% discount indicates near-term price parity depending on valuation method.
- Analyst framework: target price in RMB (28.94) reflects expected EPS progression and supports the 'Outperform' view based on projected earnings (CNY 0.89→1.45 through 2027).
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) - Risk Factors
LEPU ScienTech operates in a highly competitive, highly regulated medical-device environment. Investors should weigh a set of company-specific and market-wide risk factors that can materially affect near‑term performance and long‑term valuation.- Competition: the firm competes with established domestic players and multinational device manufacturers that have larger R&D budgets, broader distribution networks and entrenched hospital procurement relationships. Market share pressure can compress pricing and margin over time.
- Regulatory risk: changes to device classification, clinical trial requirements, registration timelines, or reimbursement policies in China, the EU, the U.S. and other markets may delay product launches or increase compliance costs.
- Input cost volatility: fluctuations in prices for key raw materials (e.g., medical‑grade polymers, electronic components, and precision metal parts) and logistics costs can raise production costs and squeeze gross margins, especially for price‑sensitive product lines.
- Product concentration: reliance on a limited number of high‑selling products exposes the company to product lifecycle risk (maturation, commoditization) and demand shifts if competing technologies or substitute therapies gain traction.
- Supply‑chain and operational risk: factory disruptions, supplier failures, quality issues, or trade/logistics interruptions (including pandemic‑related or port congestion events) can constrain inventory and revenue recognition.
- International expansion: entry into overseas markets brings geopolitical, tariff, regulatory and foreign‑exchange risks; FX volatility can translate into earnings volatility when repatriating revenue or valuing overseas assets.
| Metric (approx.) | Most recent annual / indicative figure | Implication for risk exposure |
|---|---|---|
| Annual revenue | HKD 2.1 billion (approx.) | Mid‑market scale - limits economies of scale vs. global incumbents |
| Gross margin | ~46% | Reasonable profitability but vulnerable to raw material and pricing pressure |
| Net profit margin | ~12% | Sensitive to increases in R&D, SG&A, or one‑off regulatory costs |
| R&D spend | ~8% of revenue | Moderate reinvestment; may need uplift to sustain competitive pipeline |
| Cash & equivalents | HKD 1.0 billion (approx.) | Solid liquidity cushion for near‑term operational needs and M&A optionality |
| Total debt | HKD 200 million (approx.) | Low leverage but FX and interest exposure remain if debt denominated in foreign currency |
| Top‑3 products contribution | ~65% of revenue | High concentration risk - product lifecycle and competitive displacement are material risks |
- Regulatory milestones and approval timelines in major markets (China NMPA, CE/IVDR in EU, FDA in U.S.).
- Gross‑margin trends quarterly - widening gap may indicate input‑cost pressure or pricing erosion.
- R&D pipeline progress and diversification of revenue by product line and geography.
- Inventory and days‑sales‑outstanding (DSO) metrics as indicators of demand softness or distribution issues.
- FX sensitivity: percent of revenue and costs denominated in RMB vs. USD/EUR/HKD, and hedging policies.
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) - Growth Opportunities
LEPU ScienTech is strategically positioned to capture accelerating demand in cardiovascular and interventional device markets through product expansion, R&D, distribution scale and partnerships. Key opportunity vectors include heart valves, cardiac mechanical circulatory support (MCS) devices, biodegradable technologies and deeper penetration in both domestic and international channels.- Product portfolio expansion: entering heart valve and cardiac MCS segments opens access to higher-value, high-growth submarkets with strong clinical demand.
- R&D-led differentiation: targeted investments in novel device designs, minimally invasive delivery systems and biodegradable materials can enhance clinical adoption and pricing power.
- Distribution leverage: an established sales network across China plus presence in over 160 countries enables faster roll-out and scale economies for new product introductions.
- Collaborative acceleration: partnerships with tertiary hospitals, cardiovascular centers and research institutes shorten clinical validation timelines and support reimbursement pathways.
- Demographic and epidemiological tailwinds: rising prevalence of cardiovascular disease (CVD) increases addressable patient volumes for valves, stents, implantable devices and MCS solutions.
- Sustainability alignment: biodegradable device focus meets growing regulatory and payer emphasis on long-term patient safety and reduced implant burden.
| Opportunity Area | Relevant Market Size / Metric | Estimated CAGR / Trend |
|---|---|---|
| Global heart valve market | ~$7-8 billion (2021-2022 est.) | ~6-9% CAGR (next 5-8 years) |
| Cardiac mechanical circulatory support (MCS) | ~$2-4 billion (varies by device class) | High single- to mid-teens CAGR for advanced devices |
| Cardiovascular disease burden | ~523 million people living with CVD (2019); ~17.9 million deaths/year (2019) | Rising absolute prevalence driven by aging and lifestyle factors |
| Geographic reach | Sales network: China + presence in >160 countries | Significant upside from deeper domestic penetration and emerging markets |
| Biodegradable device trend | Growing regulatory and clinical interest; rising R&D investment | Accelerating adoption as clinical evidence and reimbursement emerge |
- Commercialization levers: cross-selling to existing hospital accounts, bundling service/support contracts, and leveraging CE/CFDA/NMPA approvals to shorten market access timelines internationally.
- KPIs investors should track: new product approvals (NMPA/CE/US FDA), percentage of revenue from high-margin valve/MCS products, R&D spend as % of revenue, and sales penetration (domestic tier-1 hospitals vs. emerging market share).
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.